Pamplona

• A study of RMC-6236 in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B Recruiting
  2023-509572-42-00 3 2024-07-17 Lung Cancer
• Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting
  2023-508162-15-00 5 2024-07-12 Chronic HF and comorbid impairment of kidney function who had a recent
• Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients with Advanced … Recruiting
  2023-508178-27-00 9 2024-07-10 Participants with Advanced KRASG12C-Mutated Solid Tumors
• Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism Recruiting
  2024-511959-18-01 5 2024-07-01 Acute Pulmonary Embolism
• An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with ad … Recruiting
  2023-504199-19-00 7 2024-06-26 Solid Tumours
• A trial to learn if AZD0305 alone and in combination with other cancer treatments is safe and works in adults with multiple myeloma Recruiting
  2023-508590-89-00 7 2024-06-25 Multiple Myeloma
• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can … Recruiting
  2023-507914-28-00 10 2024-06-19 Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade
• Phase 2, randomised study of Radspherin® in patients with primary advanced epithelial cancer with peritoneal metastasis that are homologous … Recruiting
  2023-508497-28-00 4 2024-06-05 Carcinomatosis of peritoneal cavity
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients wit … Recruiting
  2022-502404-73-00 4 2024-06-03 Pancreatic ductal adenocarcinoma
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un … Recruiting
  2023-508613-17-00 5 2024-05-29 Neoplasms, Head and Neck
• A study of ASP3082 in adults with advanced solid tumors Recruiting
  2022-501590-39-00 1 2024-05-22 Solid Tumor
• Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS- … Recruiting
  2023-505929-14-00 5 2024-05-21 Systemic Lupus Erythematosus
• Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate c … Recruiting
  2023-505024-62-01 4 2024-05-16 Oligometastatic patients with castration-resistant prostate cancer
• Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy Recruiting
  2024-513601-31-00 4 2024-05-13 Acute lymphoid leukemia
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in particip … Recruiting
  2023-507305-33-00 7 2024-04-29 Patients with ER+ HER2- advanced breast cancer and patients with high-
• A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch … Recruiting
  2023-505660-11-00 5 2024-04-24 Cholangiocarcinoma (LTT, 26.0)
• RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previousl … Recruiting
  2022-500031-37-00 5 2024-04-08 ​ stage IA/IIA Hodgkin lymphoma
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participa … Recruiting
  2023-503208-94-00 6 2024-04-04 Prostate cancer
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA) Recruiting
  2023-504472-24-00 4 2024-03-19 Early Idiopathic Parkinson’s disease (PD)
• Phase I/IIa multicentre study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beau … Recruiting
  2024-514544-90-00 9 2024-03-11 Relapsed or refractory B-cell lymphoma
• A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants with Hearing Loss Due to Otoferlin Pathogenic Var … Recruiting
  2024-511342-40-00 7 2024-03-04 Congenital Hearing Loss Secondary to Biallelic Pathogenic Variants of

Showing 313–336 of 821 trials